BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bai B, Belovodskiy A, Hena M, Kandadai AS, Joyce MA, Saffran HA, Shields JA, Khan MB, Arutyunova E, Lu J, Bajwa SK, Hockman D, Fischer C, Lamer T, Vuong W, van Belkum MJ, Gu Z, Lin F, Du Y, Xu J, Rahim M, Young HS, Vederas JC, Tyrrell DL, Lemieux MJ, Nieman JA. Peptidomimetic α-Acyloxymethylketone Warheads with Six-Membered Lactam P1 Glutamine Mimic: SARS-CoV-2 3CL Protease Inhibition, Coronavirus Antiviral Activity, and in Vitro Biological Stability. J Med Chem 2021. [PMID: 34242027 DOI: 10.1021/acs.jmedchem.1c00616] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Malla TR, Brewitz L, Muntean DG, Aslam H, Owen CD, Salah E, Tumber A, Lukacik P, Strain-Damerell C, Mikolajek H, Walsh MA, Schofield CJ. Penicillin Derivatives Inhibit the SARS-CoV-2 Main Protease by Reaction with Its Nucleophilic Cysteine. J Med Chem 2022. [PMID: 35549342 DOI: 10.1021/acs.jmedchem.1c02214] [Reference Citation Analysis]
2 Costanzi E, Kuzikov M, Esposito F, Albani S, Demitri N, Giabbai B, Camasta M, Tramontano E, Rossetti G, Zaliani A, Storici P. Structural and Biochemical Analysis of the Dual Inhibition of MG-132 against SARS-CoV-2 Main Protease (Mpro/3CLpro) and Human Cathepsin-L. Int J Mol Sci 2021;22:11779. [PMID: 34769210 DOI: 10.3390/ijms222111779] [Reference Citation Analysis]
3 Neamati N. Advances Toward COVID-19 Therapies Special Issue. J Med Chem 2022. [PMID: 35138859 DOI: 10.1021/acs.jmedchem.2c00178] [Reference Citation Analysis]
4 Xu T, Xu M, Zhu W, Chen CZ, Zhang Q, Zheng W, Huang R. Efficient Identification of Anti-SARS-CoV-2 Compounds Using Chemical Structure- and Biological Activity-Based Modeling. J Med Chem 2022. [PMID: 35275639 DOI: 10.1021/acs.jmedchem.1c01372] [Reference Citation Analysis]
5 Kumar V, Kar S, De P, Roy K, Leszczynski J. Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study. SAR QSAR Environ Res 2022;:1-30. [PMID: 35380087 DOI: 10.1080/1062936X.2022.2055140] [Reference Citation Analysis]
6 Wang Z, Yang L, Zhao XE. Co-crystallization and structure determination: An effective direction for anti-SARS-CoV-2 drug discovery. Comput Struct Biotechnol J 2021;19:4684-701. [PMID: 34426762 DOI: 10.1016/j.csbj.2021.08.029] [Reference Citation Analysis]
7 Kneller DW, Li H, Galanie S, Phillips G, Labbé A, Weiss KL, Zhang Q, Arnould MA, Clyde A, Ma H, Ramanathan A, Jonsson CB, Head MS, Coates L, Louis JM, Bonnesen PV, Kovalevsky A. Structural, Electronic, and Electrostatic Determinants for Inhibitor Binding to Subsites S1 and S2 in SARS-CoV-2 Main Protease. J Med Chem 2021;64:17366-83. [PMID: 34705466 DOI: 10.1021/acs.jmedchem.1c01475] [Reference Citation Analysis]
8 Lu J, Chen SA, Khan MB, Brassard R, Arutyunova E, Lamer T, Vuong W, Fischer C, Young HS, Vederas JC, Lemieux MJ. Crystallization of Feline Coronavirus Mpro With GC376 Reveals Mechanism of Inhibition. Front Chem 2022;10:852210. [DOI: 10.3389/fchem.2022.852210] [Reference Citation Analysis]
9 Stille JK, Tjutrins J, Wang G, Venegas FA, Hennecker C, Rueda AM, Sharon I, Blaine N, Miron CE, Pinus S, Labarre A, Plescia J, Burai Patrascu M, Zhang X, Wahba AS, Vlaho D, Huot MJ, Schmeing TM, Mittermaier AK, Moitessier N. Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CLpro covalent inhibitors. Eur J Med Chem 2021;229:114046. [PMID: 34995923 DOI: 10.1016/j.ejmech.2021.114046] [Reference Citation Analysis]
10 Bai B, Arutyunova E, Khan MB, Lu J, Joyce MA, Saffran HA, Shields JA, Kandadai AS, Belovodskiy A, Hena M, Vuong W, Lamer T, Young HS, Vederas JC, Tyrrell DL, Lemieux MJ, Nieman JA. Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors. RSC Med Chem 2021;12:1722-30. [PMID: 34778773 DOI: 10.1039/d1md00247c] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]